Aromatase inhibitor shows promise for breast cancer patients
22nd Dec 2005, 01:29 GMT
Filed under: Breast Cancer, Drug Women with hormone-sensitive early breast cancer are getting benefits from the drug Novartis's Femara. The Swiss drug maker presented data at the 28th annual San Antonio Breast Cancer Symposium in Texas revealing that the aromatase inhibitor showed a benefit in starting therapy up to five years after the end of standard tamoxifen treatment. In a press relaes Novartis claimed, "Postmenopausal women who switched from placebo to Femara experienced a 69-percent reduction in the risk that their breast cancer would return." Permalink | Email this | Linking Blogs | Comments
Aromatase inhibitor shows promise for breast cancer patients related news:
- Breast cancer patients face long waits — United Press International - NewsTrack
- Breast cancer in the era of personalised medicine — Services latest news on Laboratorytalk
- Breast cancer survival rate boosted by radiotherapy — News-Medical News Feed
- New Care For Breast Cancer Patients — KLTV - Community
- Ancient Chinese remedy shows potential in preventing breast cancer — Physics Org
- Derivative Of The Sweet Wormwood Plant Shows Potential In Preventing Breast Cancer — Medical News Today RSS/XML Feed
- Breast-cancer numbers soar. — Daily New Zealand News
- Genes May Determine Cancer Drug's Effectiveness — TechNewsWorld
- Breast Cancer Treatment Site Launches to Provide Centralized Information Resource for Those Facing Breast Cancer Treatments — PR Web (The Free Wire Service) Medical
- Mayo Clinic Reports Tamoxifen Benefit For Breast-cancer Patients Tied To Inherited Gene — ScienceDaily Headlines